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Abstract
Background: Central nervous system is a common site of metastasis in NSCLC and confers
worse prognosis and quality of life. The aim of this prospective study was to evaluate the prognostic
significance of clinical-pathological factors (CPF), serum CEA levels, and EGFR and HER2 tissue-
expression in brain metastasis (BM) and overall survival (OS) in patients with advanced NSCLC.
Methods: In a prospective manner, we studied 293 patients with NSCLC in IIIB-IV clinical stage.
They received standard chemotherapy. CEA was measured prior to treatment; EGFR and HER2
were evaluated by immunohistochemistry. BM development was confirmed by MRI in symptomatic
patients.
Results:  BM developed in 27, and 32% of patients at 1 and 2 years of diagnosis with
adenocarcinoma (RR 5.2; 95% CI, 1.002–29; p = 0.05) and CEA ≥ 40 ng/mL (RR 11.4; 95% CI, 1.7–
74; p < 0.01) as independent associated factors. EGFR and HER2 were not statistically significant.
Masculine gender (RR 1.4; 95% CI, 1.002–1.9; p = 0.048), poor performance status (RR 1.8; 95%
CI, 1.5–2.3; p = 0.002), advanced clinical stage (RR 1.44; 95% CI, 1.02–2; p = 0.04), CEA ≥ 40 ng/
mL (RR 1.5; 95% CI, 1.09–2.2; p = 0.014) and EGFR expression (RR 1.6; 95% CI, 1.4–1.9; p = 0.012)
were independent associated factors to worse OS.
Conclusion: High CEA serum level is a risk factor for BM development and is associated with poor
prognosis in patients with advanced NSCLC. Surface expression of CEA in tumor cells could be the
physiopathological mechanism for invasion to CNS.
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Background
Lung cancer is the first cause of cancer death in the world.
Eighty five percent of patients are diagnosed yearly with
non-small cell lung cancer (NSCLC). Despite efforts,
innovations, and progress in diagnosis and treatment of
these patients, overall survival (OS) at 5 years of diagnosis
is only 15% [1].
The central nervous system (CNS) is a devastating and fre-
quent site of metastasis development in NSCLC. The
reported incidence of CNS metastasis in patients with
NSCLC is 54% [2] with an OS of <1 year after diagnosis
[3-5]. Age [3], clinical stage [6], gender [7], and initial
treatment period [8] are some of the reported with CNS
metastasis development-related factors in patients with
NSCLC; however, due to their lack of specificity, we are
required to detect biomarkers to predict brain metastasis
in patients with NSCLC.
Carcinoembryonic antigen (CEA, CEA-related cell adhe-
sion molecule 5, CEACAM5) is an oncofetal protein
attached to epithelial-cell apical membrane via its c-termi-
nal glycosylphosphatidylinositol anchor, a member of the
immunoglobulin superfamily of cell adhesion molecules
(IgCAMs) [9]. CEA is usually over-expressed in a variety of
neoplasms, such as colorectal, breast, bladder, gastric,
pancreatic, and lung carcinomas [10]. CEA protein levels
were found to correlate with its mRNA levels in cells and
tissues examined, suggesting that CEA overexpression in
cancer cells involves CEA-gene transcriptional activation
[9]. CEA-related cell adhesion molecules (CAMs) are
involved in cell-cell recognition and modulate cellular
processes [11]. High serum CEA levels have been associ-
ated with advanced disease and tumor relapse in resected
NSCLC [12-19]. Despite this widely reported informa-
tion, there are no studies on serum CEA levels in advanced
NSCLC and brain metastasis development.
The family of epidermal growth factor receptors (EGFRs)
plays an important role in proliferation and cell survival.
It is composed of the following four different receptors: 1)
epidermal growth factor receptor (EGFR, erbb1); 2)
HER2/neu (erbb2); 3) HER3 (erbb3), and 4) HER4
(erbb4). In NSCLC, reported incidence of EGFR tissue
expression is 43–89% [20] and it has been associated with
a worse prognosis [21]; nonetheless, evidence concerning
its role as a prognostic factor remains controversial [22-
26]. With an incidence of 25% in breast cancer, HER2 tis-
sue expression is associated with poor disease-free survival
and OS compared with patients who are HER2-negative
[27]. Recent reports correlate this with brain metastasis
development [28]. In patients with NSCLC, HER2 tissue
expression entertains an incidence of 11–32% [29] and
has been linked with worse OS at 3 and 5 years of diagno-
sis [30].
The objective of this study was to evaluate prospectively
manner the prognostic significance of clinical-pathologi-
cal factors, serum CEA levels, and EGFR and HER2 lung
expression in brain metastasis development and OS in
patients with recent diagnosis of advanced NSCLC (clini-
cal stage IIIB-IV) treated with platin-based cytotoxic
chemotherapy or EGFR inhibitors.
Methods
Patients
Between March 2005 and June 2007, patients with recent
histological diagnosis of advanced NSCLC without previ-
ous treatment and referred to the Lung cancer and Tho-
racic Tumors Clinic (Instituto Nacional de Cancerología
and Instituto Nacional de Enfermedades Respiratorias,
Mexico City, Mexico) were enrolled in this prospective
study. This work was approved by bioethical and research
committees of each institution, and patient informed con-
sent was obtained before enrollment. Histological diag-
nosis of primary NSCLC was established according to the
revised classification of lung tumors of World Health
Organization and the International Association for Lung
Cancer Study. During pre-treatment clinical evaluation,
we focused on physical examination, weigh loss, and per-
formance status (according to the Eastern Cooperative
Oncologic Group scale, ECOG). Thoracic, upper abdomi-
nal computed tomography (CT) and bone scintillography
were used in disease staging. Only patients with IIIB (T4
N0-1-2 M0 or any T N3 M0: tumor of any size that invades
mediastinum, heart, great vessels trachea, esophagus, ver-
tebral body, carina; or tumor with a malignant pleural or
pericardial effusion, or with satellite tumor nodule(s)
within the ipsilateral primary-tumor lobe of the lung [T4],
no regional lymph node metastasis [N0], metastasis to
ipsilateral peribronchial and/or ipsilateral hiliar lymph
nodes, and intrapulmonary lymph nodes involved by
direct extension of the primary tumor [N1], metastasis to
ipsilateral mediastinal and/or subcarinal lymph node(s)
[N2], or metastasis to contralateral mediastinal, contralat-
eral hiliar, ipsilateral or contralateral scalene, or supracla-
vicular lymph node(s) [N3], and no distant metastasis
[M0]) and IV clinical stage (any T any N M1: distant
metastasis present) were enrolled [31,32]. Chemotherapy
was based on platin or EGFR inhibitors. Six different
schedules were instituted, including gemcitabine, vinore-
lbine, or paclitaxel combined with cisplatin or carboplatin
and erlotinib.
Samples
Analyzed variables comprised smoking history, gender,
general condition, histology, brain metastasis develop-
ment, serum CEA levels, and EGFR and HER2 tissue
expression.BMC Cancer 2009, 9:119 http://www.biomedcentral.com/1471-2407/9/119
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CEA levels in serum were evaluated prior to chemother-
apy. CEA was measured by solid-phase, two-site sequen-
tial chemiluminescent immunometric assay (IMMULITE
2000-CEA Analyzer, Siemens, Inc., Los Angeles, CA) with
an analytical sensibility of 0.15 ng/mL and a high-dose
Hook effect at levels of >250,000 ng/mL. Serum samples
(15 μL serum) were collected using the same method for
each patient and stored if necessary at -20°C before
processing. Cut-off points for resuming tables were
selected according to the previously reported normal
value for CEA serum level (< 10 ng/mL) [10].
EGFR and HER2 tissue expression were evaluated by
immunohistochemistry (IHC). IHC was performed on
formalin-fixed, paraffin-embedded tissue sections from
primary lung tumors. 5 μm sections were placed on chem-
ically charged slides. Sections were deparaffinized and
rehydrated in a series of alcohols and xylene according to
established procedures. Following deparaffination, sec-
tions were immersed in an antigen-retrieval solution
(Dako Corporation) for 40 min at 95°C. Endogen perox-
idase was blocked with 3% H2O2 in absolute methanol for
5 min. Slides were incubated with rabbit antibody human
HER2 (Hercep Test, Dako Corporation) for 30 min, and
staining was completed using Dako Rabbit Evision Plus
Kit (Dako Corporation). The antibody binding site was
visualized using diaminobenzidine reagent for 5 min. The
slides were counterstained with Mayer's hematoxylin.
Immunostainig for EGFR was accomplished using the
monoclonal mouse antibody to EGFR (1:100, Zymed
Laboratories, San Francisco, CA). The slides were incu-
bated with peroxide block for 10 min, this followed by
incubation for 10 min with proteinase K. After incubation
of slides with primary antibody for 30 min, staining was
completed by incubation with monoclonal-labeled poly-
mer for 10 min. The antibody binding site was visualized
using diaminobenzidine reagent. Finally, the slides were
counterstained with Mayer's hematoxylin.
EGFR and HER2 were examined using light microscopy.
For EGFR, we considered negative tissue expression if the
stain was heterogeneous in ≤ 25% of the sample, and pos-
itive tissue expression if stain was homogeneous >25% of
sample. For semi-quantitative evaluation of HER2, all
slides were scored following the guidelines for scoring
HercepTest: 0, completely negative or membrane staining
in fewer than 10% of tumor cells; 1+, faint membranous
staining in >10% of the tumor cells; 2+, weak or moderate
complete staining in >10% of tumor cells, and 3+, strong
complete membrane staining in >10% of the tumor cells.
IHC was graded by a single pathologist (AAS), who was
blinded to clinical characteristics and outcomes.
Follow-up
In presence of neurological symptoms (persistent head-
ache, neurological focalization, motor deficits, or abnor-
mal behaviour), brain magnetic resonance imaging (MRI)
was performed. Monitoring of disease (including primary
endpoints, e.g., OS and brain metastasis development)
was carried out by means of clinical follow-up.
Statistical analysis
With a descriptive purpose, we resumed each continuous
variable as arithmetic mean, median and standard devia-
tion (SD), and categorical variables as proportion with
95% confidence interval (95% CI). For inferential com-
parisons, we employed Student t or Mann-Whitney U test,
according to data distribution (normal or non-normal,
determined with Kolmogorov-Smirnov test). To calculate
statistical significance between categorical variables, we
used chi-square or Fisher exact test. Statistically significant
and borderline results (p < 0.1) were included in multivar-
iate logistic regression analysis. CNS metastasis develop-
ment and OS were defined as the period from date of
histological diagnosis to date of confirmed diagnosis of
brain metastasis by MRI and to date of death, respectively;
both were analyzed with Kaplan-Meier method, and sub-
groups were compared with log-rank test. To analyze sur-
vival curves, each variable was dichotomized. HER2 tissue
expression was considered negative if IHC was classified
as 0 or +1, and positive if classified as +2 and +3. For
EGFR, tissue expression was negative or positive if IHC
was positive in <25% or ≥ 25% of tumor cells, respec-
tively. Statistically significant or borderline (p < 0.1) vari-
ables on univariate analysis were included in multivariate
analysis utilizing Cox proportional hazards model. Statis-
tical significance was determined with a p < 0.05 in a two-
sided test. SPSS software package (version 14.0; SPSS, Inc.,
Chicago, IL) was employed for data analysis.
Results
Patients and samples
Two hundred ninety three consecutive patients were pro-
spectively studied. Patient characteristics are shown in
Table 1. Mean for age was 60.7 ± 0.7 years. Only 54% of
patients had smoking history. The majority of tumors
were adenocarcinoma (65%) classified as moderate or
high histological grade (36 and 54%, respectively). Sev-
enty one percent of patients were diagnosed in a meta-
static stage, and 29% were in IIIB clinical stage. Of
patients with metastasis at time of diagnosis, 18.6% had
CNS metastasis and 7.5%, liver metastasis. Most patients
were referred to our Institute without paraffin blocks and
in others the diagnosis was based on cytopathological
samples; even, when tissue samples were available, some
of them were insufficient to perform the immunohisto-
chemistry. Because of these reasons, we only analyzed 85
biopsies of primary tumor to determine tissue expressionBMC Cancer 2009, 9:119 http://www.biomedcentral.com/1471-2407/9/119
Page 4 of 9
(page number not for citation purposes)
of EGFRs types 1 and 2, of which, 59% were positive for
EGFR and only 7% for HER2 tissue expression.
Serum levels of CEA
In 42.8, 32.3, 22.2, and 21.4% of patients, basal serum
CEA level was ≥ 10, 20, 40, and 50 ng/mL at diagnosis,
respectively (median ± standard deviation, 6.3 ± 1,021
ng/mL; range, 0.2–15,475 ng/mL). Age, gender, positive
smoking history, status performance, histological-grade of
differentiation and presence of liver metastasis at diagno-
sis were not associated to basal CEA serum levels ≥ 40 ng/
mL. However, at the bi- and multivariate analysis, factors
associated with basal CEA serum levels ≥ 40 ng/mL were
adenocarcinoma histological type (frequency of 41.3%
compared with 14.1% of patients with squamous or large-
cell histologies, RR 1.6; 95% CI, 1.4–3.4; p = 0.005) and
presence of CNS metastasis at diagnosis (frequency of
77.7% compared with 12.3% of patients without CNS
metastasis at diagnosis, RR 14.05; 95% CI, 5.7–34.4; p <
0.001).
CNS metastasis
At 1 year of diagnosis, 27% (95% CI, 23–30%) of patients
developed brain metastasis, and at 2 years, 32% (95% CI,
21–43%). As treatment for brain metastasis, only 4
patients achieved criteria to undergo radiosurgery, none
of the patients was submitted to brain surgery, and all
other patients received whole brain irradiation. Independ-
ent associated factors comprised adenocarcinoma histo-
logical type (RR 5.2; 95% CI, 1.002–29; p = 0.0002) and
CEA serum levels ≥ 40 ng/mL (RR 11.4; 95% CI, 1.7–74;
p < 0.001) (Table 2). In the subgroup analysis of patients
with adenocarcinoma histologycal type, frequency ±
standard error of CNS metastasis development at 12
months of diagnosis were 16.4 ± 0.03% (95% CI, 16.34 –
16.46%) and 67 ± 0.09% (95% CI, 66.91 – 67.09), in
patients with CEA serum levels < 40 ng/mL, and ≥ 40 ng/
mL, respectively. And at 24 months of diagnosis, fre-
quency ± standard error of CNS metastasis development
were 20.2 ± 0.05% (95% CI, 20.19 – 20.21%) and 67 ±
0.09% (95% CI, 66.82 – 67.18%) in patients with CEA
serum levels < 40 ng/mL and ≥ 40 ng/mL, respectively.
EGFR tissue expression was not statistically significant in
terms of CNS metastasis development.
Overall survival
OS was 7 ± 0.48 months. Factors associated with statistical
significance at univariate analysis with poor OS were male
gender (p = 0.02), age ≥ 60 years (p = 0.028), poor per-
formance status (ECOG III, p < 0.001), serum CEA levels
≥ 40 ng/mL (p = 0.002), and EGFR-positive tissue expres-
sion (p = 0.023). Clinical stage IV demonstrated solely a
tendency toward significance (p = 0.056) (Table 3). On
multivariate analysis, male gender (RR = 1.4; 95% CI,
1.002–1.9; p = 0.048) [Fig 1a], poor performance status
(RR 1.8; 95% CI, 1.5–2.3; p = 0.002) [Fig 1b], clinical
stage IV (RR 1.4; 95% CI, 1.02–2; p = 0.04) [Fig 1c], serum
CEA levels ≥ 40 mg/mL (RR 1.5; 95% CI, 1.09–2.2; p =
0.014) [Fig 1d], and EGFR tissue expression (RR 1.6; 95%
CI, 1.4–19; p = 0.012) [Fig 1e] were statistically signifi-
cant.
Discussion
Carcinoembryonic antigen, a glycoprotein expressed dur-
ing early fetal life, is the product of the CEACAM5-gen. Its
expression is restricted to epithelial cells, and it is found
more abundantly on apical surface of gastrointestinal epi-
thelium, but can also be found in other mucosal epithelia,
Table 1: Baseline patient characteristics
N = 293 Mean ± SE Patients
(%)
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ECOG: Eastern Oncology Cooperative Group Scale.
*Other: Squamous, Giant Cells, Undifferentiated.
CNS: Central Nervous System.
**Other: Lymph Nodes, Bones, Contralateral Lung.
EGFR: Epidermal Growth-Factor Receptor.
***: Tissue expression was determined only in 85 different
primary tumor samples (see text).BMC Cancer 2009, 9:119 http://www.biomedcentral.com/1471-2407/9/119
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such as lung [9]. In this prospective study, we found
abnormal serum CEA levels (≥ 10 ng/mL) in 43% and lev-
els ≥ 40 ng/mL in 22% of patients with advanced NSCLC.
However, 41% of patients with pathological diagnosis of
adenocarcinoma had serum CEA levels ≥ 40 ng/mL. In our
study, we found a significant association between high
CEA serum levels and adenocarcinoma in comparison
with other histological types. This observation is consist-
ent with a Japanese study, which showed association
between high CEA serum levels and primary lung adeno-
carcinoma in clinical stage I, compared with squamous
type [33].
We found that high CEA serum levels and histological
type adenocarcinoma were associated with brain metasta-
sis at time of diagnosis. Furthermore, we found that a CEA
serum level ≥ 40 ng/mL is the more important factor asso-
ciated with CNS metastasis development during follow-
up (Table 2), independent of clinical stage (IIIB or IV) and
absence or presence of liver metastasis, suggesting that
association between high CEA serum levels and brain
metastasis development are not due to tumor charge but
rather to a more invasive phenotype.
Tumors with high CEA expression could possess an
increased capacity to develop brain metastasis, and this
could be due to vascular-tumoral cell-cell adhesion proc-
esses. CEA is a member of the IgCAM superfamily and is
involved in homo and heterotypic interactions with other
closely related IgCAMs, which possess at least one immu-
noglobulin-like domain [11]. Furthermore, CEA is usually
found at higher concentrations in cerebrospinal fluid
(CSF) of patients with metastatic tumors to CNS [34].
There is strong evidence regarding the capacity of CEA to
penetrate the blood-brain barrier, behaving in a similar
manner to Igs due to their homologous molecular weights
[35,36]. Thus, CEA-positive tumor cells could bond to
brain vasculature, favoring CNS metastasis development,
similar to leukocyte transendothelial arrest and migration
through blood-brain barrier mediated by integrin-Ig
adhesion interactions [37]; in addition, this could be
explained by paraprotein-secreting cells, such as mononu-
clear cells with Ig-kappa and lambda light chains, which
preferentially pass from peripheral blood to CSF [38].
CEA could represent a molecular target in patients with
lung adenocarcinoma. CEA blockage or expression inhibi-
tion could slow or even prevent brain metastasis develop-
ment in this group of patients. Target blockade of CEA
with antibodies inhibits the cell migration, invasion, and
adhesion in vitro and in vivo in several tumor cell lines
[39]. Moreover, CEA serum levels could be a recognition
tool of patients with high risk of metastasis development,
who may benefit from CNS imaging tests prior to devel-
opment of neurological symptoms. Other cell-adhesion-
Table 2: Associated factors with CNS metastasis development
N = 293 CNS Metastasis 12 
months
% (95% IC)
CNS Metastasis 24 
months
% (95% IC)
p Univariate Analysis RR (95% CI) p Multivariate 
Analysis
Age
<60 years 20 (14.2–25.8) 36 (20.2–51.6) 0.79
≥60 years 22 (16.1–27.8) 22 (16.1–27.8)
Gender
Female 21 (13.6–27.3) 31 (12.9–48.1) 0.86
Male 22 (16.1–27.9) 33 (18.8–46.2)
Smoking History
Negative 24 (18.2–29.9) 36 (18.6–53.9) 0.22
Positive 19 (13.1–24.8) 26 (12.3–39.7)
Histology
Adenocarcinoma 28 (22.1–33.8) 31 (23.1–38.8) 0.0002 5.2 (1.002–29) 0.05
*Others 7.8 (3.9–11.7) 29 (3.5–54.4)
CEA ≥ 40 ng/mL
Negative 12 (8–15.9) 24 (11.8–35.3) <0.001 11.4 (1.7–74) 0.01
Positive 61 (45.4–76.8) 61 (45.4–76.8)
EGFR***
Positive 57 (56.6–57.3) 57 (56.6–57.3) 0.2
Negative 45 (44.6–45.3) 45 (44.6–45.3)
The endpoint for univariate analysis was CNS metastasis at 24 months.
CNS: Central Nervous System.
RR (95% CI): Relative Risk (95% Confidence Interval).
*Others: Squamous, Giant Cells, Undifferentiated.
CEA: Carcinoembryonic Antigen.
***: Tissue expression was determined only in 85 different
primary tumor samples (see text).BMC Cancer 2009, 9:119 http://www.biomedcentral.com/1471-2407/9/119
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molecular markers associated to lymph-node metastasis,
as chemokine receptors CCR7, CXCR3 and CCL21
[40,41], could be related to brain metastasis develop-
ment, thus, studies about analysis of their association
with brain metastasis development are justified.
We found that OS-associated factors were gender, func-
tional state, clinical stage, serum CEA levels, and EGFR tis-
sue expression. Masculine gender is associated with a
higher mortality risk than feminine gender. The eastern
cooperative oncology group (ECOG) analyzed 1,594
patients, obtaining median survival of 9.2 months for
females and 7.3 months for males (p = 0.004) [42], and
Visbal et al. in 2004 conducted a study of 4,618 patients,
finding a mortality risk for males of 1.2 (95% CI, 1.11–
1.3) compared with females [43]. These findings are sim-
ilar to our results [Fig. (A)]; however, they remain unex-
plained, and recent studies report contradictory results
[44,45]. Evidence oriented in favor of females (best sur-
vival and local control post-surgery) is based on a differ-
ent etiologic possibility: best tolerance to chemotherapy
and possibly an estrogen role in lung oncogenesis. EGFR
tissue expression increased the mortality risk in our
patients by 60% compared with those not expressing
EGFR. As showed by meta-analysis in 2002, detection of
EGFR tissue expression by IHC was associated with a
Table 3: Associated factors with overall survival
N = 293 Mean ± SE (months) p Univariate Analysis RR (95% CI) p Multivariate Analysis
Age
<60 years 8.33 ± 0.7 0.028 1.09 (0.8–1.47) 0.53
≥60 years 6.03 ± 0.7
Gender
Female 8.03 ± 0.57 0.02 1.4 (1.002–1.9) 0.048
Male 6.2 ± 0.41
Smoking History
Negative 7.2 ± 0.8 0.14
Positive 6.4 ± 0.6
ECOG
1 9.9 ± 0.3 <0.001 1.8 (1.5–2.3) 0.002
27 . 0 7  ±  0 . 5 9
3 3.83 ± 0.4
Clinical Stage
III B 9.4 ± 1.76 0.056 1.44 (1.02–2) 0.04
IV 7 ± 0.86
Histology
Adenocarcinoma 6.2 ± 0.8 0.67
*Others 7.8 ± 0.69
CNS Metastasis at diagnosis
Negative 7 ± 0.6 0.9
Positive 4.7 ± 1
Liver Metastasis at diagnosis
Negative 7.03 ± 0.5 0.51
Positive 5.13 ± 2.6
CEA ≥ 40 ng/mL
Negative 7.8 ± 0.6 0.002 1.5 (1.09–2.2) 0.014
Positive 3.87 ± 0.65
EGFR***
Positive 3.8 ± 1 0.023 1.6 (1.4–19) 0.012
Negative 8.7 ± 2
HER2***
Positive 4.9 ± 2 0.3
Negative 4.2 ± 2
SE: Standard Error.
ECOG: Eastern Cooperative Oncology Group Scale.
*Others: Squamous, Giant Cells, Undifferentiated.
CNS: Central Nervous System.
RR (95% CI): Relative Risk (95% Confidence Interval).
CEA: Carcinoembryonic Antigen.
EGFR: Epidermal Growth-Factor Receptor.
***: Tissue expression was determined only in 85 different
primary tumor samples (see text).BMC Cancer 2009, 9:119 http://www.biomedcentral.com/1471-2407/9/119
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Independent factors associated with overall survival Figure 1
Independent factors associated with overall survival. RR (95% CI): Relative Risk (95% Confidence Interval). ECOG: 
Eastern Cooperative Ocology Group Scale. CS: Clinical Stage. CEA: Serum Carcinoembryonic Antigen Level. EGFR: Epidermal 
Growth-Factor Receptor.BMC Cancer 2009, 9:119 http://www.biomedcentral.com/1471-2407/9/119
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worse prognosis (mortality, RR 1.13; 95% CI, 1–1.28)
[46]. As previously reported, HER2 tissue expression had
a low incidence in our population, and we found no asso-
ciation between HER2 expression and brain metastasis
development or survival. Nonetheless, this may be due to
low frequency; thus, we cannot conclude about its impact
on brain metastasis development or survival.
It is convenient to mention that we found differences
between CNS metastasis prensence at diagnosis and over-
all survial rates in our cohort patients, according to cut-off
levels of CEA serum levels ≥ 10, 20 30 y 40 ng/mL; how-
ever, related differences to both variables were more noto-
rious with a cut-off point of CEA serum level ≥ 40 ng/mL,
thus we selected this value to perform our subsequent
analyses.
In many neoplasms, high serum CEA levels have been pre-
viously described as a predictor of residual disease or
tumor relapse in patients without normal-range serum
levels after surgery [47]. We prospectively reported that
patients with CEA serum levels ≥ 40 ng/mL had an
increased mortality risk of 50% as an independent feature.
In a retrospective study in 70 patients in early stages of
NSCLC, those with high CEA serum levels demostrated an
OS at 3 years of diagnosis of 0%, compared to 18% in
patients with normal levels. In fact, Iwasaki et al. proposed
a formula to evaluate mortality risk based on CEA serum
levels, histological type, and presence of positive medias-
tinal lymph nodes [48]. High CEA serum levels may
reflect micrometastatic disease, although we detect no dif-
ferences of CEA serum levels between patients in IIIB and
in IV clinical stage. This observation suggests that the
prognostic role of high CEA serum levels could be not due
to other factors aside from tumor charge. CEA comprises
an important tumor marker associated with several phys-
iopathological processes of tumorogenesis, such as
immunological defense, cell adhesion, cell survival, and
metastasis, and its expression is induced by hypoxia-
inducible factor α (HIF-α), suggesting that CEA plays an
important role as a microenvironmental factor during
tumorogenesis and confers a worse prognosis [9,49,50].
Conclusion
High serum CEA level at diagnosis is an independent
prognostic factor of CNS metastasis development and sur-
vival in patients with NSCLC. Surface expression of CEA
in tumor cells could be a mechanism of invasion to CNS
through immunoglobulin-related transport in blood-
brain barrier. CEA may represent a potential molecular
target.
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